このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

2026年5月11日 更新者:Liping Dou

A Study of CD19/CD22 CAR-T Cell Therapy as First-line Consolidation Treatment in Patients With Follicular Lymphoma

The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.

調査の概要

詳細な説明

Follicular lymphoma (FL) is the most common subtype of indolent B-cell lymphoma. In the rituximab era, the overall prognosis of patients has significantly improved; however, the disease remains incurable with substantial heterogeneity. A considerable proportion of patients, particularly those with high-risk features (such as high follicular lymphoma international prognostic index score, high tumor burden, and high risk of early progression), exhibit insufficient depth of response to standard immunochemotherapy (e.g., R-CHOP, BR) or experience early relapse and drug resistance.

In recent years, first-line treatment strategies for FL have undergone profound changes. While traditional immunochemotherapy remains the cornerstone, its toxicity and limited efficacy in specific high-risk populations are increasingly recognized. On one hand, optimized chemotherapy strategies (e.g., the zanubrutinib plus BR regimen) have shown extremely high complete response rates (CRR of 81.5%) in early-phase studies, offering hope for improved efficacy. On the other hand, the exploration of chemotherapy-free regimens has achieved breakthrough progress. The RELEVANCE study confirmed the feasibility of the R² regimen (lenalidomide plus rituximab) as first-line treatment for FL, demonstrating non-inferior efficacy to traditional chemotherapy with a distinct safety profile. Furthermore, the PERSPECTIVE study showed that the combination of ibrutinib and rituximab (IR) was significantly superior to rituximab monotherapy in previously untreated FL patients unfit for chemotherapy. More encouragingly, the venetoclax, ibrutinib, and obinutuzumab (VIG) chemotherapy-free combination achieved a remarkable 12-month complete response rate of 92% in a phase II study.

However, even after achieving complete or partial remission with standard induction therapy, high-risk FL patients still face a substantial risk of disease progression and relapse. Currently, there is no established consolidation strategy following first-line induction therapy for these patients to further deepen response and reduce long-term relapse risk. The 2024 National Comprehensive Cancer Network (NCCN) guidelines for the management of high-risk FL after induction therapy are largely limited to close observation or involved-site radiotherapy, lacking more aggressive interventional strategies.

Chimeric antigen receptor T-cell (CAR-T) therapy has established an important role in relapsed/refractory B-cell lymphomas. Notably, in patients with relapsed/refractory FL who have received ≥3 prior lines of therapy, CAR-T therapy (e.g., lisocabtagene maraleucel, liso-cel) has demonstrated potential advantages over bispecific antibodies in efficacy outcomes (objective response rate, complete response rate, progression-free survival). Given the ability of CAR-T therapy to induce deep and durable molecular remissions, and the fact that its adverse event profile (e.g., cytokine release syndrome) is generally manageable with current protocols, moving CAR-T therapy forward as first-line consolidation represents a promising strategy. This approach may help eliminate minimal residual disease in high-risk FL patients, thereby reducing the risk of early progression (progression of disease within 24 months, POD24) and improving long-term survival outcomes.

Therefore, this study aims to evaluate the efficacy and safety of CD19/CD22 dual-targeted CAR-T cell immunotherapy as a consolidation strategy following standard first-line induction therapy in patients with high-risk follicular lymphoma, with the goal of providing a new treatment option for this population with an unmet medical need.

研究の種類

介入

入学 (推定)

20

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100853
        • 募集
        • Chinese PLA General Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • 1. With the patient's consent and signed informed consent form, willing and able to comply with the planned visits, research treatments, laboratory tests, and other experimental procedures;
  • 2. CD19 and/or CD22-positive follicular lymphoma (FL) confirmed by histology according to the WHO classification:

    1. The patient's disease is still evaluated as partial response (PR) after induction treatment with standard first-line chemotherapy regimen, or
    2. The patient's disease reaches complete response (CR) after induction treatment with standard first-line chemotherapy regimen, but there are high-risk factors at the time of onset;
  • 3. The possible high-risk factors for the patient's onset of the disease are as follows: Presence of at least one of the following high-risk features at diagnosis:

    1. Follicular Lymphoma International Prognostic Index (FLIPI-1) score of 3-5 or FLIPI-2 score of 3-5;
    2. Presence of any lymph node or extranodal mass >6 cm in diameter;
    3. Significant infiltration of CD68+ or CD163+ macrophages by immunohistochemistry;
    4. Gene sequencing revealing TP53 or NOTCH1 mutation;
    5. Presence of 1p36 deletion or 1q amplification;
    6. Next-generation sequencing (NGS)-defined high-risk mutation-based 7-gene Follicular Lymphoma International Prognostic Index (m7-FLIPI) subtype.
  • 4. Age range from 18 to 85 years old, male or female;
  • 5. Subjects with physical fitness status scores ranging from 0 to 2 in the Eastern Cooperative Oncology Group (ECOG) in the United States;
  • 6. Expected survival period from the date of signing the informed consent form is greater than 3 months;
  • 7. HGB ≥ 60g/L;
  • 8. The absolute value of neutrophils in peripheral blood is ≥ 1000/μl, and the platelet count is ≥ 45000/μl;
  • 9. Liver and kidney function, as well as heart and lung function, meet the following requirements:

    1. Total bilirubin (TBIL) ≤ 1.5 times the upper limits of normal (ULN), except for subjects with Gilbert's syndrome;
    2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN;
    3. Serum Creatinine (Cr) ≤ 1.5 times ULN or Creatinine Clearance Rate (CCr) ≥ 60mL/min, estimated based on the Cockcroft Gault formula;
    4. The left ventricular ejection fraction (LVEF) of the heart is ≥ 50%. Echocardiography (ECHO) confirms no pericardial effusion and no clinically significant arrhythmia;
    5. Baseline transcutaneous oxygen saturation under indoor ventilation>92%;
    6. No clinically significant pleural effusion;
  • 10. Participants with pregnancy plans must agree to take contraceptive measures for a continuous period of 6 months from before enrollment in the study until the end of the study; If the subject is pregnant or suspected of being pregnant, the researcher should be notified immediately.

Exclusion Criteria:

  • 1. Have received any form of chimeric antigen receptor cell therapy or other genetically modified T cell therapy;
  • 2. Has a history of severe immediate hypersensitivity reactions to aminoglycoside antibiotics and other essential medications;
  • 3. Known history of human immunodeficiency virus (HIV) infection or active hepatitis B virus (HBV) infection, or any uncontrolled active systemic infection requiring intravenous antibiotics (active HBV infection is defined as:

    1. HBV DNA quantification ≥ 2000 IU/ml;
    2. ALT ≥ 2 times the normal upper limit value;
    3. Exclude hepatitis caused by the disease itself, medication, or other reasons; All three conditions must be met simultaneously. If a patient is diagnosed with active HBV infection at the time of initial diagnosis and becomes non active HBV infection after anti HBV treatment, they can be included in this study under the premise of sufficient anti HBV treatment;
  • 4. Non hematological tumors (such as lymphoma) associated liver and kidney dysfunction: ALT>3 times the upper limit of normal, AST>3 times the upper limit of normal, TBIL>2 times the upper limit of normal, serum creatinine clearance rate<30 mL/min;
  • 5. History of myocardial infarction, cardiac angioplasty or coronary stent implantation, unstable angina, active arrhythmia, or other clinically significant cardiovascular diseases within the 12 months prior to enrollment;
  • 6. Other serious medical diseases may have an impact on this study (such as diabetes, gastric ulcer, other serious respiratory and circulatory diseases, severe autoimmune diseases or congenital immune defects, severe infection and inability to be effectively controlled), as well as other diseases with high risk of disease change;
  • 7. Has a history of severe immediate hypersensitivity reactions to any medication necessary for use in this study; History of severe allergy to biological products (including antibiotics);
  • 8. Female subjects who are currently pregnant or breastfeeding (with potential risks to the fetus or infant from pre-treatment chemotherapy regimens);
  • 9. The researchers determined that the subjects were unable to complete all the required visit surveys or diagnostic procedures (including medium - and long-term follow-up visits) as per the study protocol, had poor willingness to participate in the study, were unwilling to join and fully comply with the study arrangements, and had insufficient compliance with the study by the subjects and their families. The decision-making power belongs to the researcher;
  • 10. The subjects who have previously suffered from other malignant tumors cannot be included in this study unless they are disease-free and have not received any form of anti-tumor treatment for at least 3 years (except for skin tumors of non malignant melanoma and in situ cancers occurring in the cervix, bladder, breast, etc.);
  • 11. History of receiving live vaccines within 6 weeks prior to initiating the pre-treatment plan;
  • 12. Those who have undergone large-scale surgical treatment (excluding lymph node biopsy) within the past 14 days, or those who are expected to undergo large-scale surgical treatment during the treatment process;
  • 13. There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients deemed unsuitable by the researchers to participate in this study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:CD22/CD19 CAR-T cell immunotherapy
patients with high-risk invasive Follicular Lymphoma who accept targeted CD22/CD19 CAR-T cell immunotherapy for first-line consolidation therapy
Autologous T cells were collected and genetically modified to express chimeric antigen receptors targeting CD19 and CD22. Following lymphodepleting chemotherapy, patients received a single intravenous infusion of CD19/CD22 CAR-T cells.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
1-year progression free survival rate (1-year-PFSR)
時間枠:2 year after treatment
The 1-year progression-free survival rate (1-year PFSR) is defined as the proportion of patients who are alive and progression-free at 1 year after CAR-T cell infusion.
2 year after treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
全生存期間(OS)
時間枠:治療後2年
全生存期間(OS)とは、治療開始から患者が何らかの理由で死亡するまでの期間を指します。
治療後2年
イベントフリー生存率 (EFS)
時間枠:治療後2年
イベントフリー生存期間(EFS)は、特定の期間中に有害事象のない患者の生存期間を評価するために、臨床試験で一般的に使用されるエンドポイント指標です。 これらの有害事象には、疾患の進行、死亡、治療計画の変更、および重篤な副作用の発生が含まれますが、これらに限定されません。
治療後2年
再発率
時間枠:治療後2年
再発率とは、治療後にリンパ腫が再発した患者の割合を指します。
治療後2年
disease free survival (DFS)
時間枠:2 years after treatment
Disease free survival (DFS) refers to the time from treatment to the first lymphoma recurrence.
2 years after treatment
progression free survival (PFS)
時間枠:2 years after treatment
Progression free survival (PFS) refers to the time from treatment to the first lymphoma progression or death of the patient for any reason.
2 years after treatment
duration of response (DOR)
時間枠:2 years after treatment
Duration of Response (DOR) refers to the time from the first assessment of a lymphoma as a complete or partial response to the first assessment of PD (Progressive Disease) or death from any cause.
2 years after treatment
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
時間枠:2 years after treatment
All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
2 years after treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月1日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2028年1月1日

試験登録日

最初に提出

2026年5月4日

QC基準を満たした最初の提出物

2026年5月11日

最初の投稿 (実際)

2026年5月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月14日

QC基準を満たした最後の更新が送信されました

2026年5月11日

最終確認日

2026年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する